BRCA1 and BRCA2: different roles in a common pathway of genome protection
- PMID: 22193408
- PMCID: PMC4972490
- DOI: 10.1038/nrc3181
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Abstract
The proteins encoded by the two major breast cancer susceptibility genes, BRCA1 and BRCA2, work in a common pathway of genome protection. However, the two proteins work at different stages in the DNA damage response (DDR) and in DNA repair. BRCA1 is a pleiotropic DDR protein that functions in both checkpoint activation and DNA repair, whereas BRCA2 is a mediator of the core mechanism of homologous recombination. The links between the two proteins are not well understood, but they must exist to explain the marked similarity of human cancer susceptibility that arises with germline mutations in these genes. As discussed here, the proteins work in concert to protect the genome from double-strand DNA damage during DNA replication.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
Comment in
-
Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.Nat Rev Cancer. 2012 May 24;12(5):372-3; author reply 372. doi: 10.1038/nrc3181-c1. Nat Rev Cancer. 2012. PMID: 22525576 No abstract available.
-
BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.Nat Rev Cancer. 2012 May 24;12(5):372; author reply 372. doi: 10.1038/nrc3181-c2. Nat Rev Cancer. 2012. PMID: 22525577 No abstract available.
Similar articles
-
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.Curr Biol. 2009 Mar 24;19(6):524-9. doi: 10.1016/j.cub.2009.02.018. Epub 2009 Mar 5. Curr Biol. 2009. PMID: 19268590 Free PMC article.
-
New complexities for BRCA1 and BRCA2.Curr Biol. 2001 Aug 21;11(16):R668-76. doi: 10.1016/s0960-9822(01)00389-x. Curr Biol. 2001. PMID: 11525763 Review.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
-
Hallmarks of 'BRCAness' in sporadic cancers.Nat Rev Cancer. 2004 Oct;4(10):814-9. doi: 10.1038/nrc1457. Nat Rev Cancer. 2004. PMID: 15510162 Review.
-
A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a _targetable Defect in Homologous Recombination Repair.Cancer Res. 2021 Dec 15;81(24):6171-6182. doi: 10.1158/0008-5472.CAN-21-1415. Epub 2021 Sep 21. Cancer Res. 2021. PMID: 34548335 Free PMC article.
Cited by
-
An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.Int J Mol Sci. 2024 Oct 10;25(20):10876. doi: 10.3390/ijms252010876. Int J Mol Sci. 2024. PMID: 39456660 Free PMC article.
-
Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.Oncol Lett. 2024 Oct 8;28(6):595. doi: 10.3892/ol.2024.14728. eCollection 2024 Dec. Oncol Lett. 2024. PMID: 39430730 Free PMC article.
-
The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.Mol Cell Biol. 2015 Apr;35(7):1254-68. doi: 10.1128/MCB.01152-14. Epub 2015 Jan 26. Mol Cell Biol. 2015. PMID: 25624349 Free PMC article.
-
Role of H3K9 demethylases in DNA double-strand break repair.J Cancer Biol. 2020;1(1):10-15. doi: 10.46439/cancerbiology.1.003. J Cancer Biol. 2020. PMID: 32696030 Free PMC article.
-
Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b.Front Genet. 2016 Aug 31;7:143. doi: 10.3389/fgene.2016.00143. eCollection 2016. Front Genet. 2016. PMID: 27630665 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous